Table 3.
Analysis of patients who received levetiracetam (LEV) and valproate (VPA) monotherapy based on seizure type
| Seizure type | Antiepileptic drugs (AEDs | Remission group | Uncontrolled group | P value |
|---|---|---|---|---|
| ALLa | VPA | 21 | 19 | 0.417 |
| LEV | 16 | 21 | ||
| GTCSb | VPA | 27 | 9 | 0.036 |
| LEV | 15 | 15 | ||
| MSc | VPA | 22 | 18 | 0.524 |
| LEV | 23 | 14 |
Remission group = no seizure for at least 2 years.
a
No seizure for all seizure types in juvenile myoclonic epilepsy (JME) patients.
b
No seizure for only JME patients with generalized tonic‐clonic seizure.
c
No seizure for JME patients with MS.